Ascendis Pharma

Achondroplasia on ultrasound
#Ascendis Pharma #Clinical trials #Paediatrics

Ascendis provides update on achondroplasia programmes

Ascendis Pharma has provided updates across its achondroplasia programme, including data from the COACH and ApproaCH trials.  Combination therapy update  The company announced that treatment with the combination of once-weekly TransCon CNP and once-weekly TransCon hGH has continued to demonstrate durable growth in children with… Read More

#News

#Ascendis Pharma #BioIndustry Association #Cancer therapy #CHMP #Clinical trial #Diversity #European Medicines Agency #FDA #Gene therapy #Oncology #Paediatrics #Rare disease #uniQure #University of Queensland #Women in STEM

DDW Highlights: 10 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, figures showed the number of women in biotech leadership has stalled. Elsewhere, could… Read More

#Podcasts

Stamp of approval
#Accelerated assessment #Ascendis Pharma #FDA #Paediatrics #Rare disease

FDA approves first once-weekly achondroplasia therapy

The US Food & Drug Administration (FDA) has granted approval for Yuviwel (navepegritide) under its Accelerated Approval Program.  Navepegritide is the only once-weekly treatment indicated to increase linear growth in children one years of age and older with achondroplasia with open epiphyses and the only one to provide continuous systemic… Read More

#News #Regulatory

#Ascendis Pharma #Chronic hypoparathyroidism #European Commission

EC grants marketing authorisation for chronic hypoparathyroidism drug 

The European Commission (EC) has granted marketing authorisation for YORVIPATH (palopegteriparatide) as replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism.   YORVIPATH is Ascendis Pharma's prodrug of parathyroid hormone (PTH 1-34), administered once daily. Ascendis plans its first EU launch of YORVIPATH in January 2024 in Germany.  “Each… Read More

#News #Regulatory